Findings from Prometheus Biosciences’ Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that PRA023, an anti-TL1A monoclonal antibody, is potentially safe and effective in ulcerative colitis and Crohn’s disease.
Novartis’ Kisqali, combined with endocrine therapy, offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer, the company announced Tuesday.
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II – two Phase III studies in Alzheimer’s disease.
“We are surprised and disappointed” that the drug did not show superiority over the placebo, Chief Executive Officer John Kollins said.
The company announced that its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.
This paper explains the challenges patients face in traditional trial settings as well as how Aparito overcomes these challenges; how remote video is able to capture real-world evidence (RWE) while improving the patient experience; and how Aparito provides more meaningful patient data while protecting patient privacy.
Two Phase III trials of Genentech (Roche)’s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion (BRVO), showing non-inferiority to Regeneron’s Eylea.
Mirum Pharmaceuticals announced that Livmarli oral solution met its primary endpoint in the Phase III MARCH study in young patients with progressive familial intrahepatic cholestasis.
